529509-52-2Relevant academic research and scientific papers
5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases
Mastalerz, Harold,Chang, Ming,Chen, Ping,Fink, Brian E.,Gavai, Ashvinikumar,Han, Wen-Ching,Johnson, Walter,Langley, David,Lee, Francis Y.,Leavitt, Kenneth,Marathe, Punit,Norris, Derek,Oppenheimer, Simone,Sleczka, Bogdan,Tarrant, James,Tokarski, John S.,Vite, Gregory D.,Vyas, Dolatrai M.,Wong, Henry,Wong, Tai W.,Zhang, Hongjian,Zhang, Guifen
, p. 4947 - 4954 (2007)
Pyrrolotriazine dual EGFR/HER2 kinase inhibitors with a 5-((4-aminopiperidin-1-yl)methyl) solubilizing group were found to be superior to analogs with previously reported C-5 solubilizing groups. New synthetic methodology was developed for the parallel sy
C-5 Modified indazolylpyrrolotriazines
-
, (2008/06/13)
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
